Package Insert: Information for the Patient
Everolimus Avalon 2.5 mg Tablets EFG
Everolimus Avalon 5 mg Tablets EFG
Everolimus Avalon 10 mg Tablets EFG
Read this package insert carefully before taking this medicine, as it contains important information for you.
Everolimus is used to treat adult patients with:
-Advanced tumors known as neuroendocrine tumors that originate in the stomach, intestine, lung, or pancreas. It is administered if the tumors are not operable and do not produce specific hormones or other natural substances related to them.
-Advanced kidney cancer (advanced renal cell carcinoma), when other treatments (designated as anti-VEGF treatment) have not helped to stop their disease.
Everolimus Avalon will only be prescribed by a doctor with experience in cancer treatment. Follow the doctor's instructions carefully. They may be different from the general information contained in this prospectus. If you have any doubts about Everolimus Avalon or the reason why you have been prescribed this medication, consult your doctor.
Do not take Everolimus Avalon
If you think you may be allergic, consult your doctor.
Warnings and precautions
Consult your doctor before starting to take everolimus:
Everolimus may also:
Inform your doctor if you are scheduled to receive radiation therapy soon, or if you have received radiation therapy previously.
Inform your doctorif you experience these symptoms.
During treatment, you will have blood tests performed periodically. These tests will determine the number of blood cells (white blood cells, red blood cells, and platelets) to check if everolimus is having an undesirable effect on these cells. You will also have blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels. These tests are done because these may be affected by everolimus treatment.
Children and adolescents
Everolimus should not be administered to children or adolescents (under 18 years old).
Other medications and Everolimus Avalon
Everolimus may affect how other medications work. If you are taking other medications at the same time as everolimus, your doctor may change the dose of everolimus or the other medications.
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
The following may increase the risk of side effects with everolimus:
The following may reduce the effectiveness of everolimus:
You should avoid using these medications during everolimus treatment. If you are taking any of them, your doctor may prescribe a different medication, or may change your everolimus dose.
Taking Everolimus Avalon with food and drinks
Do not take grapefruit or grapefruit juice while taking everolimus. It may increase the amount of everolimus in your blood, possibly to a harmful level.
Pregnancy, breastfeeding, and fertility
Pregnancy
Everolimus may cause harm to the fetus and is not recommended during pregnancy. Inform your doctor if you are pregnant or think you may be pregnant. Your doctor will discuss with you whether you should take this medication during pregnancy.
Women who may become pregnant should use a highly effective contraceptive method during treatment and for 8 weeks after treatment is completed. If, despite these measures, you think you may be pregnant, consult your doctor before taking more everolimus.
Breastfeeding
Everolimus may harm the breastfeeding baby. Do not breastfeed during treatment and for 2 weeks after the last dose of everolimus. Inform your doctor if you are breastfeeding.
Female fertility
Some patients treated with everolimus have experienced amenorrhea (absence of menstrual periods).
Everolimus may affect female fertility. Inform your doctor if you want to have children.
Male fertility
Everolimus may affect male fertility. Consult your doctor if you want to be a father.
Driving and operating machinery
If you feel abnormally tired (fatigue is a very common side effect), be extra careful when driving or operating machinery.
Everolimus Avalon contains lactose
Everolimus Avalon contains lactose (milk sugar). If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
The recommended dose is 10 mg, once a day. Your doctor will inform you about how many everolimus tablets you should take.
If you have liver problems, your doctor may start treatment with a lower dose of everolimus (2.5; 5; or 7.5 mg per day).
If you experience some adverse effects while taking everolimus (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period of time or permanently.
Take everolimus once a day, more or less at the same time, always with food or always without food.
Swallow the tablets whole with a glass of water. The tablets should not be chewed or crushed.
If you take more Everolimus Avalon than you should
If you forgot to take Everolimus Avalon
If you have forgotten a dose, take the next dose at the time it is due. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Everolimus Avalon
Do not stop treatment with everolimus unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
STOP treatment with everolimus and seek medical help immediately if you experience any of the following signs of an allergic reaction:
-Intense itching of the skin, with red rash or lumps on the skin.
The serious side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
potentially
Rare(may affect up to 1 in 1,000 people)
If you experience any of these side effects, report them to your doctor immediately as they may be fatal.
Other possible side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
low red blood cell count (anemia)
Common(may affect up to 1 in 10 people))
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
If these adverse reactions worsen, report them to your doctor and/or pharmacist. Most side effects are mild to moderate and usually disappear if treatment is interrupted for a few days.
Reporting of adverse reactions
If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use: https://www.notificaram.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and in the blister pack. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Store in the original packaging to protect it from light and moisture.
Open the blister pack just before taking the tablets.
Do not use this medication if you observe that the packaging is damaged or shows signs of manipulation.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications that you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications that you no longer need. By doing so, you will help protect the environment.
Composition of Everolimus Avalon
Appearance of the product and contents of the package
Everolimus Avalon 2.5 mg: elongated tablets, white to slightly yellow in color, approximately 10 mm long, 4 mm wide, and 3 mm high, with the inscription "2.5" on one face.
Everolimus Avalon 5 mg: elongated tablets, white to slightly yellow in color, approximately 12 mm long, 5 mm wide, and 4 mm high, with the inscription "5" on one face.
Everolimus Avalon 10 mg: elongated tablets, white to slightly yellow in color, approximately 15 mm long, 6 mm wide, and 5 mm high, with the inscription "10" on one face.
Everolimus Avalon 2.5 mg is available in packages containing 30x1 or 90x1 tablets.
Everolimus Avalon 5 mg and Everolimus Avalon 10 mg are available in packages containing 10x1, 30x1, or 90x1 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
AVALON LABORATORIOS S.L.,
C/ La Cora, number 4, Local 1,
18006 Granada, Spain
Responsible for manufacturing
Ardena Pamplona, S.L.
Polígono Mocholí. C/ Noáin, 1
31110 Noáin (Navarra), Spain
or
Laboratori Fundació DAU
C/ C, 12-14, Pol. Ind. Zona Franca,
08040 Barcelona, Spain
or
Docuchem, SLU
C/ Pic de Peguera, 11 A.0.07,
17003 Girona, Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Member state name | Medicine name |
Germany | EverolimusTAM2.5 mg Tabletten EverolimusTAM5 mg Tabletten Everolimus TAM 10 mg Tabletten |
Spain | Everolimus Avalon 2.5 mg comprimidos EFG Everolimus Avalon 5 mg comprimidos EFG Everolimus Avalon 10 mg comprimidos EFG |
Italy | Everolimus TAM |
Last review date of this leaflet:November 2023
The detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.